Posted by Michael Wonder on 20 Dec 2022
F2G announces FDA filing acceptance of new drug application for Olorofim for the treatment of invasive fungal infections
19 December 2022 - Application submitted under priority review with PDUFA target action date set for 17 June 2023.
F2G today announced that the US FDA has accepted for filing its new drug application for olorofim for the treatment of invasive fungal infections in patients who have limited or no treatment options.
